splice mutation in a family with autosomal dominant aniridia. The mutation is a single nucleotide change which, although occurring within an exon, affects the splice junction consensus and results in skipping of that exon.
(J Med Genet 1995;32: [488] [489] Aniridia is a sight threatening congenital malformation of the eye which is chiefly characterised by severe iris hypoplasia. l A candidate aniridia gene, PAX6, was isolated from chromosomal region lip 13 
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, f w w . _ _ group.bmj.com on June 21, 2017 -Published by http://jmg.bmj.com/ Downloaded from exon 12 were PCR amplified from the genomic DNA of II-2 and 12. The splice acceptor sequence at the 5' boundary of exon 12 was shown by direct sequencing of PCR products to be normal (data not shown). However, direct sequencing of the 3' boundary of exon 12 showed that the last nucleotide of the exon was heterozygous (G wild type, C mutant) in the patient (fig 2A) . The 3'-terminal residue is a G in 77% of exons and forms part of the consensus sequence CAG/GTAAGT (the last base of the exon is underlined) for recognition of the splice donor by complementary base pairing to U 1 snRNA, a component of the spliceosome.'2 The wild type exon 12 splice donor (CAG/GTGAG) already differs from the consensus at two positions (underlined); presumably the patient's mutation (CAC/ GTGAGC) reduces the complementarity further so that the splice site is no longer recognised by the snRNA. Although pathological mutations involving substitution ofthe last base of an exon are rare, exon skipping is known to be a consequence of this type of mutation. 12-14 The patient's mutation creates a site at the genomic level for the restriction endonuclease MaeII (ACGT). MaeII digestion of a genomic PCR product containing the splice donor confirmed the presence of the mutation in the affected members of the family but not the unaffected member (fig 2B) .
Although the genomic mutation presented here is new, the consequence of the mutation, namely skipping of exon 12, is the same as that in patient "VIGMA" described by Hanson etal.7
Translation ofthe exon 12 deleted PAX6 mRNA would result in a protein product in which the C-terminal half of the PST rich domain was replaced by a nonsense peptide. GAL4 fusion experiments have shown that the ability of the PAX6 PST rich region to behave as an activation domain is severely compromised ifit is truncated at the C-terminal end." This observation may explain the molecular basis of aniridia in the present family and in patient "VIGMA".7
